The effectiveness evidence was derived from a synthesis of published studies.
moderate or severe migraine pain who took one dose of triptan for the initial treatment of their migraine pain experienced either a response at 2 hours or no response. Those experiencing a response moved to mild pain (MP2) or pain-free (PF2). Those having no response remained at moderate or severe pain. Patients who attained a PF2 response could experience a recurrence, move to mild pain, or be pain-free during the remainder of the 24-hour period. Patients with mild pain at 2 hours could experience a recurrence (moderate or severe pain) or no recurrence (mild or no pain) throughout the remainder of the 24-hour period. A graphical representation of the model was provided. The time horizon of the model was 24 hours.
Outcomes assessed in the review
The outcomes estimated from the literature were:
the 2-hour response therapeutic gain, the 2-hour pain-free therapeutic gain, the 24-hour sustained pain-free rate, and the recurrence rate.
Study designs and other criteria for inclusion in the review
A published meta-analysis of 53 studies was used. However, few details of the study were reported.
Sources searched to identify primary studies
Not relevant.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two publications of the same meta-analysis provided the clinical data.
Methods of combining primary studies
Investigation of differences between primary studies
Not stated. 
Results of the review

Methods used to derive estimates of effectiveness
The authors made some assumptions about the doses taken.
Estimates of effectiveness and key assumptions
It was assumed that: patients with PF2 who experienced a subsequent recurrence took a second triptan dose;
patients with PF2 who subsequently suffered from mild pain took only one triptan dose;
patients with PF2 who moved to sustained pain-free did not take any additional triptan doses; and patients with mild pain at 2 hours who experienced a recurrence took a second triptan dose.
Measure of benefits used in the economic analysis
The summary benefit measures used were the NNT and the DNT to achieve 100 successfully treated patients. These were calculated using data derived from the published meta-analysis through the decision model. NNT was chosen as a measure of therapeutic effectiveness because it takes placebo effects, which are likely to occur in clinical trials, into account.
Direct costs
The analysis of the costs was performed from the viewpoint of the third-party payer. It included only the costs of the triptans, which were estimated using average wholesale prices minus 15% per dose for each triptan. The quantities of resources used and unit costs were presented. Extensive information on the calculation of costs using the modelling approach was reported. Resource use was based on authors' assumption around the doses required for each patient.
Discounting was not relevant as the costs were incurred during a short timeframe. The price year was not explicitly reported but the costs were derived from 2004 prices.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency
US dollars ($).
Sensitivity analysis
A univariate sensitivity analysis was carried out to assess the robustness of the results of the analysis to a higher proportion of nonresponders at 2 hours who took an additional dose. The authors defined the alternative value.
Estimated benefits used in the economic analysis
The NNT was: 542 with almotriptan 12.5 mg; 361 with eletriptan 40 mg; 573 with naratriptan 2.5 mg;
597 with rizatriptan 5 mg and 458 with rizatriptan 10 mg;
448 with sumatriptan 50 mg and 490 with sumatriptan 100 mg; and 464 with zolmitriptan 2.5 mg and 450 with zolmitriptan 5 mg. The DNT was: 579 with almotriptan 12.5 mg;
388 with eletriptan 40 mg; 600 with naratriptan 2.5 mg;
662 with rizatriptan 5 mg and 516 with rizatriptan 10 mg;
488 with sumatriptan 50 mg and 534 with sumatriptan 100 mg; and 507 with zolmitriptan 2.5 mg and 502 with zolmitriptan 5 mg.
Cost results
The costs per dose were: 
Synthesis of costs and benefits
The costs and benefits were combined by calculating the cost to successfully treat 100 patients, which was based on the DNT.
The cost to successfully treat 100 patients was:
$9,073 with almotriptan 12.5 mg;
$5,630 with eletriptan 40 mg;
$11,136 with naratriptan 2.5 mg;
$10,579 with rizatriptan 5 mg and $8,246 with rizatriptan 10 mg;
$7,779 with sumatriptan 50 mg and $8,549 with sumatriptan 100 mg;
$7,549 with zolmitriptan 2.5 mg and $8,499 with zolmitriptan 5 mg.
Given that eletriptan 40 mg had the lowest cost and the lowest NNT, it was the dominant treatment.
The sensitivity analysis showed that an increase in the proportion of nonresponders at 2 hours who took an additional dose did not alter the conclusions of the analysis.
